Evidence map›Paper›PMID 35269550›Full record

ReviewInternational journal of molecular sciences2022

Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract.

Yuan Zhang, Juhura G Almazi, Hui Xin Ong, Matt D Johansen, Scott Ledger, Daniela Traini, Philip M Hansbro, Anthony D Kelleher, Chantelle L Ahlenstiel

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Potential of siRNA in COVID-19 therapy: Emphasis onFrontiers in bioengineering and biotechnology · 2023
    Review
  14. Article
  15. Article
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Yuan ZhangKirby Institute, UNSW, Sydney, NSW 2052, Australia.ORCID 0000-0003-3270-1082
Juhura G AlmaziRespiratory Technology, Woolcock Institute of Medical Research, Sydney, NSW 2037, Australia.ORCID 0000-0003-2939-0308
Hui Xin OngRespiratory Technology, Woolcock Institute of Medical Research, Sydney, NSW 2037, Australia.
Matt D JohansenCentre for Inflammation, Faculty of Science, Centenary Institute and University of Technology Sydney, Sydney, NSW 2050, Australia.ORCID 0000-0001-5553-5270
Scott LedgerKirby Institute, UNSW, Sydney, NSW 2052, Australia.
Daniela TrainiRespiratory Technology, Woolcock Institute of Medical Research, Sydney, NSW 2037, Australia.ORCID 0000-0002-7173-017X
Philip M HansbroCentre for Inflammation, Faculty of Science, Centenary Institute and University of Technology Sydney, Sydney, NSW 2050, Australia.ORCID 0000-0002-4741-3035
Anthony D KelleherKirby Institute, UNSW, Sydney, NSW 2052, Australia.
Chantelle L AhlenstielKirby Institute, UNSW, Sydney, NSW 2052, Australia.ORCID 0000-0002-4238-7237
UNSW Sydney · AUWoolcock Institute of Medical Research · AUUniversity of Technology Sydney · AU

Funding

National Health and Medical Research Council 1128012National Health and Medical Research Council 1175134National Health and Medical Research Council 2011467National Health and Medical Research Council APP1149990National Health and Medical Research Council APP1173363
6 · The paper itself

Abstract

Since December 2019, a pandemic of COVID-19 disease, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly spread across the globe. At present, the Food and Drug Administration (FDA) has issued emergency approval for the use of some antiviral drugs. However, these drugs still have limitations in the specific treatment of COVID-19, and as such, new treatment strategies urgently need to be developed. RNA-interference-based gene therapy provides a tractable target for antiviral treatment. Ensuring cell-specific targeted delivery is important to the success of gene therapy. The use of nanoparticles (NPs) as carriers for the delivery of small interfering RNA (siRNAs) to specific tissues or organs of the human body could play a crucial role in the specific therapy of severe respiratory infections, such as COVID-19. In this review, we describe a variety of novel nanocarriers, such as lipid NPs, star polymer NPs, and glycogen NPs, and summarize the pre-clinical/clinical progress of these nanoparticle platforms in siRNA delivery. We also discuss the application of various NP-capsulated siRNA as therapeutics for SARS-CoV-2 infection, the challenges with targeting these therapeutics to local delivery in the lung, and various inhalation devices used for therapeutic administration. We also discuss currently available animal models that are used for preclinical assessment of RNA-interference-based gene therapy. Advances in this field have the potential for antiviral treatments of COVID-19 disease and could be adapted to treat a range of respiratory diseases.

Indexed as

AnimalsCOVID-19Drug Delivery SystemsHumansModels, GeneticNanoparticlesPandemicsRNAi TherapeuticsRNA, Small InterferingSARS-CoV-2RNA, Small InterferingCOVID-19glycogen nanoparticlesinhalationlipid nanoparticlesnanomedicinenanoparticle-capsulated drug deliverypolymer nanoparticlessiRNA

Identifiers

PMID35269550
PMCPMC8909959
OpenAlexW4214553809

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.